IOL Chemicals & Pharmaceuticals Ltd dividend

The Dividend per Share of IOL Chemicals & Pharmaceuticals Ltd is ₹ 4 as of 2023 .a1#The Dividend Payout of IOL Chemicals & Pharmaceuticals Ltd changed from 4.77 % on March 2019 to 16.78 % on March 2023 . This represents a CAGR of 36.95% over 4 years. a1#The Latest Trading Price of IOL Chemicals & Pharmaceuticals Ltd is ₹ 413.75 as of 26 Jul 15:30 .a1#The Market Cap of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 2077 crore on March 2022 to ₹ 1660 crore on March 2023 . This represents a CAGR of -10.58% over 2 years. a1#The Revenue of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 570.17 crore to ₹ 511.44 crore over 8 quarters. This represents a CAGR of -5.29% a1#The EBITDA of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 60.95 crore to ₹ 57.04 crore over 8 quarters. This represents a CAGR of -3.26% a1#The Net Pr of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 34.67 crore to ₹ 27.62 crore over 8 quarters. This represents a CAGR of -10.74% a1#

IOL Chemicals and Pharmaceuticals Ltd is a leading organic chemicals manufacturer and supplier in India. The company manufactures active pharmaceutical ingredient, organic chemicals and intermediates. The company was incorporated in the year 1986. The company manufactures and supplies industrial chemicals and bulk drugs for use in various pharmaceutical applications. Their portfolio includes industrial chemicals, industrial organic chemicals and bulk drugs. The company has two segments namely chemicals and pharmaceuticals. Under the chemical division, the company manufactures bulk chemicals, such as acetic acid and specialty chemicals, including ethyl acetate and acetic anhydride. Under pharmaceuticals division, the company manufactures active pharmaceutical ingredient, Ibuprofen. The company has two manufacturing units namely API Unit and Chemical Unit located in Punjab. API Unit manufactures Ibuprofen with the installed Capacity of 10 MTPD. Chemical Unit manufactures organic chemicals such as Glacial Acetic Acid, Ethyl Acetate, Acetic Anhydride, Mono chloro acetic Acid, Acetyl Chloride and Iso butyl Benzene. The company is having their presence in over 40 countries across the world, which includes Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt, and many others. They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy. DS Group, Cipla, Uflex Industries, ITC Ltd, ICI Paints, Asian Paints, Pidillte, Rallis India, Hindustan Polymide, Gujarat Super Phosphate and Avon Organics Ltd etc. The capacity enhancement project and Multi Product PPIs Plant and other pharmaceutical intermediate products with a CAPEX of Rs 130 crore was completed in 2012. The Company undertook another project of multi product plant for manufacture active pharmaceutical ingredients and upgrading of R&D facilities involving a CAPEX of Rs 58.41 crore. G Drugs and Pharmaceuticals Limited (GDPL) was merged with Company, through The Board for Industrial and Financial Reconstruction (BIFR), vide its order dated 15 March 2012, with appointed date of 1 April 2010. The said Merger was made effective on 20 April 2012 and consequently GDPL ceased to exit from that date. During the current year 2016-17, the Company converted its existing multiple purpose plant into a dedicated ibuprofen manufacturing facility and resulting to its conversion, the ibuprofen manufacturing facility increased from 6200 TPA to 7200 TPA. During year 2017-18, Unit III to manufacture Fenofi brate, Clopidogrel and Lamotrigine Project was set up which costed Rs 16.48 crore. The company also setup Unit IV for manufacturing Metformin an anti-diabetic drug with a capacity of 3000 MT per annum with project cost of Rs 10.02 crore. It enhanced installed capacity of Ibuprofen from 7200 TPA to 10000 TPA by debottlenecking and re-engineering the plant in the month of August 2018. During year 2019, the Company has enhanced installed capacity of Metformin from 3,000 TPA to 4,000 TPA with a capex of Rs 2.71 crore; it set up Unit V o manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 MT per annum with capex of Rs 19.26 crore; it further enhanced existing manufacturing facilities of Ibuprofen from 10,000 TPA to 12,000 TPA and Iso Butyl Benzene from 9,000 TPA to 12,000 TPA in May 2019 with capex of Rs 12.10 crore. During 2020, the Company set up 'Unit VI', with an installed capacity of 240 MT per annum, which costed Rs 33.83 Crore, to manufacture 'Pantoprazole' and has started its trial production. During 2021, the Company set up an another Unit-7 for manufacturing Metformin with an additional capacity of 7,200 MT per annum for project costing Rs 28 cr. It installed new manufacturing facilities 'Unit-8' to manufacture Ibuprofen Derivatives and other Pharma Products during FY 2020-21. It increased existing manufacturing facilities of Ethyl Acetate from 87,000 MT per annum to 100,000 MT per annum in Chemical segment during 2021-22. During the year 2022-23, IOL- Foundation was incorporated as wholly owned subsidiary company. The Company set up multi product manufacturing facilities Unit 10' for manufacturing pharma APIs. It identified to manufacture Fenofibrate, Lamotrigine etc in this unit. Further, it also initiated the project for installation of new manufacturing facilities (Unit-9) for manufacturing Gabapentin and other Pharma products during the year, which is under implementation.